5:57 PM
Oct 17, 2012
 |  BC Extra  |  Company News

Samsung's rituximab biosimilar trial halted in two countries

Samsung Group (Seoul, South Korea) has "temporarily halted" a clinical trial of its biosimilar version of autoimmune and cancer drug MabThera rituximab in two countries, according to the EU clinical trials register. The trial's listing states that it was halted in the Czech Republic...

Read the full 210 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >